Drugs / Influenza Virus Quadrivalent Inactivated Vaccine
last change Oct 2025 re-read 2 minutes ago

Influenza Virus Quadrivalent Inactivated Vaccine

also known as IIV4

Vaccine

Developed for
influenza
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID)

Trials 3 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT03318315 Feb 2018 → Jul 2019 avian influenza National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 42 trials
Phase 4 NCT03673345 Sep 2018 → Dec 2020 influenza National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 4 NCT03328325 Dec 2017 → Feb 2020 influenza National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05755620 Comparator Apr 2023 → Oct 2025 influenza National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Influenza Virus Quadrivalent Inactivated Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT03318315
3

NCT03673345

NCT03328325

NCT05755620

Known as IIV4 “A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes...” NCT05755620
2

“0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240” NCT03328325

“one dose of seasonal influenza vaccine (IIV4)” NCT03318315

Modality Vaccine “A seasonal quadrivalent inactivated influenza vaccine (IIV4)” NCT03318315
Route Intramuscular “0.5 ml dose of IIV4 vaccine intramuscularly” NCT03318315